NOSTRUM LABORATORIES, INC.

1800 N Topping Ave, Kansas City, MO 64120. Tel: 816 308 4636 Fax: 816 308 4975

June 1, 2022

Division of Dockets Management (HFA-305)
Food and Drug Administration
Department of Health and Human Resources
5630 Fisher Lane, Room 1061
Rockville, MD 20852

Re: Oxycodone Hydrochloride and Acetaminophen Oral Solution

SUITABILITY PETITION

Dear Sir or Madam,

Nostrum Laboratories, Inc. (NLI) submits this petition pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, and in accordance with 21 C.F.R. § 10.30, requesting the Commissioner of the Food and Drug Administration to declare that the drug product Oxycodone Hydrochloride and Acetaminophen Oral Solution, in dosage strengths containing 2.5 mg of oxycodone hydrochloride and 325 mg of acetaminophen per 5 mL (hereafter referred to as the 2.5 mg/325 mg per 5 mL strength), containing 7.5 mg of oxycodone hydrochloride and 325 mg of acetaminophen per 5 mL (hereafter referred to as the 7.5 mg/325 mg per 5 mL strength) and 10 mg of oxycodone hydrochloride and 325 mg of acetaminophen (hereafter referred to as the 10 mg/325 mg per 5 mL strength) are suitable for review under an application pursuant to 505(j) under Federal FD&C Act, as amended.

NLI has already received an approval for 5 mg/325 mg per 5 mL strength under original ANDA 201448 and would like to amend the ANDA with these additional strengths through a Prior Approval Supplement (PAS).

A. Actions Requested

The petitioner requests that the Commissioner of the Food and Drug Administration declare that Oxycodone Hydrochloride and Acetaminophen Oral Solution, in strengths of 2.5 mg/325 mg per 5 mL, 7.5 mg/325 mg per 5 mL and 10 mg/325 mg per 5 mL strengths, are suitable for review under an Abbreviated New Drug Application (ANDA) supplement (PAS), pursuant to section 505(j) of the Federal Food, Drug and Cosmetic Act, as amended.

The reference listed drug product (RLD) upon which our ANDA 201448 was approved and this petition is based, is Roxicet (Oxycodone hydrochloride and Acetaminophen) Oral Solution, 5 mg /325 mg per 5 mL, A089351 owned by Hikma Pharmaceuticals USA Inc.
The *Approved Drug Products with Therapeutic Equivalence Evaluations*, also known as the Electronic Orange Book, has currently the Roxicet as “Discontinued” and lists Abhai LLC’s

Oxycodone Hydrochloride and Acetaminophen Oral Solution, 5 mg /325 mg per 5 mL, A211499 product as the RS (Attachment 1).

Thus, this petition seeks a change in the strengths of the oxycodone hydrochloride component (2.5 mg, 7.5 mg and 10 mg oxycodone), from that of the listed drug product(s).

B. Statement of Grounds

- The specific *RLD* upon which this Suitability Petition is based is Roxicet (Oxycodone Hydrochloride and Acetaminophen) Oral Solution, 5 mg /325 mg per 5 mL, A089351 owned by Hikma Pharmaceuticals USA Inc. (previously owned by Roxane Laboratories) and approved on 12/03/1986), a drug that is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate (see RLD Prescribing Information (PI) in Attachment 2).

- The proposed new strengths, 2.5 mg/325 mg per 5 mL, 7.5 mg/325 mg per 5 mL and 10 mg/325 mg per 5 mL will contain the same active ingredient as the RLD; the same dosage form (solution); and be administered via the same route of administration (oral).

- The proposed dosage strengths of oxycodone hydrochloride of 2.5 mg, 7.5 mg and 10 mg per 5 mL of drug product fall within the dosage range in the approved labeling of the RLD and NLI. The usual adult dosage is 5 mL (one teaspoonful) every 6 hours as needed for pain. The total daily dose of acetaminophen should not exceed 4 grams.
  The usual adult dosage of oxycodone hydrochloride and acetaminophen oral solution USP is as follows:

Strength	Usual Adult Dose	Maximum Daily Dose
2.5 mg/325 mg	5 mL/10 mL (one or two teaspoonful) every 6 hours	12 teaspoonful (60 mL)
5 mg/325 mg*	5 mL (one teaspoonful) every 6 hours	12 teaspoonful (60 mL)
7.5 mg/325 mg	5 mL (one teaspoonful) every 6 hours	8 teaspoonful (40 mL
10 mg/325 mg	5 mL (one teaspoonful) every 6 hours	6 teaspoonful (30 mL)

*Approved strength under RLD and NLI's ANDA 201448

- The proposed dosage strengths of the oxycodone hydrochloride of 2.5 mg, 7.5 mg and 10 mg per 5 mL, will allow for a more suitable "Titration and Maintenance of Therapy**:** Individually titrate Oxycodone Hydrochloride and Acetaminophen Oral Solution to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving Oxycodone Hydrochloride and Acetaminophen Oral Solution to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [*see WARNINGS*]." as per the RLD prescribing information (see Attachment 2).

- The labeling of the proposed drug product will be the same as the currently approved labeling for the RLD except for changes required because of the difference of manufacturer and the difference in strengths as proposed under this Suitability Petition (see proposed NLI's package insert and medication guide for the proposed 2.5 mg/325 mg per 5 mL, 7.5 mg/325 mg per 5 mL and 10 mg/325 mg per 5 mL in Attachment 3).

- Note that the FDA has already approved the drug product Oxycodone/Acetaminophen with these strengths 2.5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg in a solid dosage form (oral tablet) and also the strength of 10 mg oxycodone hydrochloride per 5 mL for Mikart, LLC's ANDA 202142 for Oxycodone Hydrochloride and Acetaminophen Oral Solution, 10 mg/300 mg per 5 mL.

- As per 21 CFR 320.22(b)(3), an oral solution product, the bioavailability and bioequivalence is self-evident if it meets certain criteria: contains the same active in the same concentration and dosage form as the RLD and contains no inactive ingredient or other change in formulation from the RLD drug product that may significantly affect the absorption of the active.

- For all the above reasons and because this drug product has been marketed for over 25 years, having a TE code of AA, the proposed strengths of 2.5 mg/325 mg per 5 mL, 7.5 mg/325 mg per 5 mL and 10 mg/325 mg per 5 mL of Oxycodone Hydrochloride and Acetaminophen Oral Solution drug product do not pose any safety or efficacy issues or concerns that would warrant the conduct of clinical trials or otherwise preclude the approval of these dosage strengths under an ANDA supplement, and should approve this petition.

C. Environmental Impact

The petitioner claims a categorical exclusion under 21 CFR 25.31.

D. Economic Impact

The petitioner does not believe that this is applicable in this case, but will agree to provide such an analysis if requested by the Agency.

E. Certification

The undersigned certifies that to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner that are unfavorable to the petition.

All inquiries regarding this correspondence should be directed to the attention of the undersigned at 732-993-6210 and/or via facsimile at 816-308-4975.

Sincerely,

Zoia Ploscaru

Digitally signed by Zoia Ploscaru
Date: 2022.06.01 11:03:24 -04'00'

Zoia Ploscaru,
Vice President, Regulatory Affairs
Nostrum Laboratories, Inc.
1800 N Topping Ave
Kansas City, MO 64120
Tel: 732-993-6210
Fax: 816-308-4975
Email: zploscaru@nostrumlabs.com